271 results about "Neutralizing antibody" patented technology

The invention discloses a lysosome targeted chimera based on Sortilin and application thereof. The lysosome targeted chimera comprises a ligand molecule of a lysosome targeted receptor and a ligand molecule of a targeted protein to be degraded, wherein the ligand molecule and the ligand molecule are connected through a linker; the lysosome targeting receptor is Sortilin, and the ligand molecule of the lysosome targeting receptor is a polypeptide targeting the Sortilin; the protein to be degraded is membrane protein or extracellular protein. Furthermore, the polypeptide of the targeted Sortilin is connected with an enzyme response sequence and an integrin receptor targeting sequence. According to the invention, the Sortilin-combined ligand neurotensin is functionally coupled with the neutralizing antibody or polypeptide of overexpression protein in targeted tumor or inflammatory diseases, and the Sortilin-combined ligand neurotensin has obvious treatment gain in malignant solid tumor and psoriasis models. The discovery promotes the transformation potential of the lysosome participating in the biological agent, and provides a dual strategy for realizing accurate degradation through receptor recruitment and microenvironment induction.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody 1D3 for detecting a porcine epidemic diarrhea virus antibody and application of the monoclonal antibody 1D3. The CDR sequences of the heavy chain variable region are respectively shown as SEQ ID NO.1-3, and the CDR sequences of the light chain variable region are respectively shown as SEQ ID NO.4-6. The antibody can specifically recognize PEDV / S1 protein, binding of the antibody can be competitively blocked by a PEDV specific neutralizing antibody in serum, and the antibody is suitable for establishing a blocking ELISA method. A detection tool based on the antibody has high specificity and sensitivity, and the blocking rate to PEDV positive serum is higher than 50%. The invention can be used for preparing a detection kit or evaluating the immune effect of a vaccine, and provides an efficient and accurate technical means for PEDV infection diagnosis and immune monitoring.

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody 1D3 for detecting porcine epidemic diarrhea virus (PEDV) and its applications. Its heavy chain variable region CDR sequences are SEQ ID NO. 1-3, and its light chain variable region CDR sequences are SEQ ID NO. 4-6. This antibody specifically recognizes the PEDV / S1 protein, and its binding can be competitively blocked by PEDV-specific neutralizing antibodies in serum, making it suitable for establishing a blocking ELISA method. Detection tools based on this antibody exhibit high specificity and sensitivity, with blocking rates exceeding 50% against PEDV-positive serum. This invention can be used to prepare detection kits or evaluate vaccine immunization efficacy, providing an efficient and accurate technical means for PEDV infection diagnosis and immune monitoring.

The invention provides bovine ephemeral fever virus positive serum as well as a preparation method and application thereof. The preparation method comprises the following steps: culturing bovine ephemeral fever virus by using MDBK suspension cells, inactivating by using beta-propiolactone, concentrating by using a 500kd hollow fiber column to obtain an antigen solution, and emulsifying the antigen solution and 61VG adjuvant according to a mass ratio of 1: 1.5 to prepare the vaccine; carrying out primary immunization and secondary immunization on the receptor, collecting blood of which the serum neutralizing antibody titer is greater than 1: 4096 14-21 days after the secondary immunization, and separating to obtain positive serum. The positive serum can be used for specific test, identification test and the like of the bovine ephemeral fever virus, can also be used for preparing related reagents, kits and standard substances, and provides efficient and normative technical support for prevention and control of bovine ephemeral fever.

The present disclosure relates generally to assays that determine the presence of neutralizing antibodies (NAbs) in a sample of a subject treated with a drug.

The invention provides a preparation method and application of a platelet-based targeting oncolytic virus delivery preparation, effective loading of oncolytic viruses is realized by infecting platelets with the oncolytic viruses, and meanwhile, the cellular structure of the platelets can be used as a physical barrier, so that the platelet-based targeting oncolytic virus delivery preparation is prepared. The tumor targeting drug delivery system shields the neutralizing and removing effects of in-vivo neutralizing antibodies / complements / removing cells on the oncolytic viruses, so that the oncolytic viruses can enter the body in a systematic drug delivery mode, tumor targeting drug delivery of the oncolytic viruses is achieved through the tumor targeting capacity of platelets, and the success of intravenous drug delivery and tumor targeting of the oncolytic viruses is achieved. The invention provides a technical support and a new idea for wider and more effective treatment of cancers, and has a good application prospect.

The invention relates to the field of veterinary vaccines, in particular to a porcine pseudorabies virus antigen, a porcine pseudorabies subunit vaccine as well as a preparation method and application of the porcine pseudorabies virus antigen and the porcine pseudorabies subunit vaccine. The porcine pseudorabies virus antigen is porcine pseudorabies virus gD protein, and the amino acid sequence of the porcine pseudorabies virus gD protein is as shown in SEQ ID NO: 1. The porcine pseudorabies subunit vaccine prepared from the porcine pseudorabies virus antigen is simple in preparation method, high in neutralizing antibody value, strong in antigen immunity, capable of effectively activating immune response of a body and capable of playing a good immune protection role on porcine pseudorabies.

Provided are an RNA vaccine for porcine epidemic diarrhea and a preparation method therefor. The RNA vaccine is obtained by means of gene synthesis, in-vitro transcription, and lipid nanoparticle encapsulation, which can rapidly respond to the currently prevalent new PEDV strains, reduces the research and production cycle of new vaccine development, and provides an effective technical approach for the prevention and control of newly mutated highly virulent strains. The prepared RNA vaccine for porcine epidemic diarrhea has high production efficiency, can induce relatively high levels of porcine epidemic diarrhea virus neutralizing antibodies and binding antibodies in vivo, effectively reducing the occurrence of diarrhea in piglets, and thus holds great promotional value for the prevention and control of porcine epidemic diarrhea.

The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

Related to the field of prevention and treatment of respiratory diseases, and disclosed a method for preparing a preventive mRNA vaccine against human respiratory syncytial virus. In some embodiments, the mRNA vaccine comprises an antigen-encoding mRNA and lipid nanoparticles. In some embodiments, the mRNA sequence utilizes an improved 5'UTR / 3'UTR sequence and codon optimization methods for efficient translation of the target protein. In some embodiments, the mRNA vaccine expresses an RSV F protein that is used as an antigen, wherein the sequence of the RSV F protein is optimized to achieve stable RSV pre-F protein expression. After immunization, the mRNA vaccine induces high levels of RSV F protein-specific binding antibody titer and neutralizing antibody titer in mice.

The invention discloses preparation and application of porcine reproductive and respiratory syndrome virus circular RNA (Ribonucleic Acid) and a vaccine. The circular RNA encodes and expresses GP5 protein optimized by the porcine reproductive and respiratory syndrome virus and M protein optimized by the porcine reproductive and respiratory syndrome virus. The optimized circular RNA molecule is prepared into a vaccine to successfully induce a high-level neutralizing antibody in a pig body, so that the proportion of CD4 + IFN-gamma + and CD8 + IFN-gamma + cells in PBMC cells is remarkably increased, the lymphocyte proliferation activity after specific stimulation of a virus antigen is remarkably improved, and the protection of the porcine reproductive and respiratory syndrome virus is effectively realized. The invention provides a basis for preparing the RNA vaccine for preventing and / or treating the porcine reproductive and respiratory syndrome virus.

The present application provides a detection method and use for neutralizing antibodies for therapeutic monoclonal antibodies, which is a CLB NAb assay developed through target-based drug depletion and drug-based NAb extraction for CMAB009 with high drug and target tolerance. Acid is typically used in the pretreatment of a sample to dissociate the drug / NAb complex. In order to improve the treatment effect, a two-step method involving an amphiphilic method and a bead method is adopted. Initially, EGFR-coated magnetic beads (target beads) are used to eliminate the majority of free drugs in a sample. Subsequently, after acid dissociation of the sample, NAb is captured with beads. NAb is neutralized and eluted by acid, and a biotinylated drug is added into an EGFR-coated flat plate for detecting NAb. A comprehensive experiment strategy is implemented, meanwhile, drug interference is relieved, and target tolerance is enhanced. Through troubleshooting and optimization, NAb determination is verified to be used for clinical sample analysis, so that the NAb is successfully applied to III-stage clinical immunogenicity NAb detection of CMAB009. The result shows that the integrated detection optimization strategy can greatly improve the key performance characteristics of CLB NAb detection, so that the potential immunogenicity and the influence of the potential immunogenicity on better biological development can be evaluated more reliably.

The invention discloses a portable immunochromatography device for detecting an African swine fever virus neutralizing antibody and application thereof.The device comprises a reading module, a sample preparation module and a detection module, the sample preparation module and the detection module are integrally connected up and down, and the sample preparation module is sequentially provided with a sample adding hole, a filtering chromatography cavity and a communicating pipe which are communicated from top to bottom; a filtering chromatography part is arranged in the filtering chromatography cavity, the detection module is provided with a fluorescence immunochromatography test strip and a shell, the fluorescence immunochromatography test strip is located in the shell, a sample pad, a fluorescence marker pad, an NC membrane and a water absorption pad of the fluorescence immunochromatography test strip are sequentially overlapped and adhered to a PVC bottom plate, and the two ends of a conduction pipe are communicated with the filtering chromatography cavity and the shell respectively. One end of the fluorescence immunochromatography test strip is located below the filtration chromatography component, the other end of the fluorescence immunochromatography test strip is located above the sample pad, the water absorption pad of the fluorescence immunochromatography test strip and the NC membrane are sequentially inserted into the reading module, and the reading module is connected with the shell through a buckle and reads a quality control line and a detection line of the inserted NC membrane.

The invention relates to the technical field of biological medicine, and discloses a titer determination method of a specific immune globulin neutralizing antibody, which comprises the following steps: step 1, preparing a cell maintenance fluid; 2, preparation of a virus solution for neutralization: diluting viruses (cytomegalovirus, syncytial virus and EV71 virus) to 100CCID50 by using a diluent according to the virus titer; step 3, diluting the test sample: carrying out double series dilution on the intravenous injection human immune globulin, the tetanus human immune globulin, the rabies human immune globulin and the human immune globulin until no cytotoxicity exists; 4, diluting a standard substance; 5, virus back dripping; step 6, neutralizing viruses; step 7, preparing cells for the test; step 8, infection; and 9, judging a result. According to the present invention, the accurate detection on the titer of the neutralizing antibody of the specific immune globulin can be achieved, and the cytotoxicity influence of the test sample and the fringe effect during the detection process can be removed so as to ensure the detection accuracy.

The present invention provides: a novel human monoclonal antibody that binds to the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and neutralizes SARS-CoV-2; an antigen-binding fragment thereof; a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof; therefore, provided are: a human monoclonal antibody against SARS-CoV-2 coronavirus that binds to the S protein of the SARS-CoV-2 coronavirus and neutralizes the viral activity thereof including an immune escape mutation; an antigen-binding fragment thereof; a nucleic acid encoding the same; and a pharmaceutical composition for the treatment or prevention of SARS-CoV-2 coronavirus infection, comprising the antibody or the antigen-binding fragment thereof.

Provided are nucleic acid molecules encoding mutant Seneca Valley Virus (SVV) that evade neutralizing antibodies with a binding specificity to SVV, as well as nanoparticles containing rapamycin and SVV or mutant SVV. The mutant SVV comprise one or more mutations in one or more SVV epitopes that prevent binding of the mutant SVV to the neutralizing antibodies. The one or more mutations of the mutant SVV may be in one or more SVV epitopes. The epitopes may be inVP1, VP2, and / or VP3 subunits of SVV. Also provided are methods of producing and using the mutant SVV for treating cancer. Also provided are methods of treating a subject comprising administering to the subject the nanoparticles comprising SVV, or mutant SVV, and rapamycin. Also provided are methods of treating a subject comprising administering to the subject SVV or mutant SVV, and cyclophosphamide.

The invention discloses a rabies vaccine and a preparation method thereof. The rabies virus G truncated mutant protein comprises a circular RNA (Ribonucleic Acid) molecule for coding rabies virus G truncated mutant protein and a pharmaceutically acceptable carrier, wherein the amino acid sequence of the rabies virus G truncated mutant protein is as shown in SEQ ID No.13 or a degenerate sequence thereof, and the nucleotide sequence is as shown in SEQ ID No.14 or a degenerate sequence thereof; the nucleotide sequence of the circular RNA molecule is as shown in SEQ ID No. 20. At present, RNA vaccines for resisting rabies virus infection are not applied in batches, the optimized rabies virus G protein circular RNA molecules and the optimized lipid nanoparticles are used for preparing the vaccines, and the process can be industrially amplified. The animal can be induced to generate a high-level neutralizing antibody and a more lasting drug effect only by injecting a low-dose circular RNA vaccine (16 [mu] g / vaccine) once, the vaccine is good in safety and stability, and a basis is provided for industrial preparation and application of the vaccine.

The present invention discloses mutants of wild-type RSV F protein. The binding experiment of pre-fusion conformation trimer-specific monoclonal antibody AM14 shows that the mutant provided in the embodiment of the present disclosure can have strong binding activity with AM14 monoclonal antibody, while the wild-type RSV F protein before artificial mutation has no binding activity with AM14 monoclonal antibody. The results of accelerated stability test show that the mutant provided in the embodiment of the present disclosure is placed in a 37°C environment for 4 weeks, and the binding activity of AM14 monoclonal antibody has no obvious change. The results of animal immunization experiments show that compared with the wild-type RSV F protein before artificial mutation, the mutant provided in the embodiment of the present disclosure can induce the production of higher titers of neutralizing antibodies.

The invention relates to the technical field of biological medicine, and particularly discloses a monoclonal neutralizing antibody for resisting respiratory syncytial virus and application of the monoclonal neutralizing antibody. The antibody provided by the invention can identify non-denatured RSV (L) protein through ELISA (enzyme-linked immunosorbent assay), but cannot identify denatured RSV (D) protein, and is a kappa IgG2b type antibody. The molecular marker is 0.0001 mu g / ml-1 mu g / ml, can positively recognize the RSV Pre-F protein, and has a gradient effect. The antibody can be used as a neutralizing active antibody in an ELISA double-antibody sandwich method, can be used for detecting the in-vitro potency of the RSV PreF protein, and plays an important role in evaluating the vaccine activity in the vaccine research and development process.

The invention discloses a completely human neutralizing antibody for resisting abrus precatorius toxin and application of the completely human neutralizing antibody, and belongs to the field of biological medicine. The antibody comprises a specific immunoglobulin heavy chain variable region and a specific immunoglobulin light chain variable region, the amino acid sequence of the heavy chain variable region is a sequence as shown in SEQ ID NO: 1 or a sequence with homology of 70% or more with the heavy chain variable region, and the amino acid sequence of the light chain variable region is a sequence as shown in SEQ ID NO: 2 or a sequence with homology of 70% or more with the light chain variable region. The anti-abrus precatorius toxin full-human neutralizing antibody disclosed by the invention has high affinity activity, and can effectively neutralize the toxicity of abrus precatorius toxin in vivo and in vitro, so that the anti-abrus precatorius toxin full-human neutralizing antibody can be effectively applied to poisoning emergency treatment and treatment of abrus precatorius toxin.

The invention discloses a therapeutic target CD40 related to multiple myeloma bone diseases and application of a monoclonal antibody of the therapeutic target CD40. On one hand, it is found that formation and osteogenic differentiation of primary cilia of BMSCs can be effectively recovered by adding a CD40 neutralizing antibody into an MM-BMSCs co-culture system; on the other hand, the CD40 neutralizing antibody is found to reduce bone destruction and tumor load in a Vk * MYC myeloma mouse model. CD40 is expected to become a potential target spot for treating multiple myeloma bone diseases and has a very wide application prospect in the field of medical research.

The present invention relates to a novel vaccine against severe fever with thrombocytopenia syndrome virus (SFTSV). According to the invention, after the SFTSV vaccine is injected in vivo, the formation speed of Gn and Gc proteins can be obviously accelerated. Besides, the vaccine can effectively stimulate humoral immune response, for example, a specific neutralizing antibody aiming at a virus antigen is induced to generate, so that a remarkable protection effect aiming at SFTSV is provided for an individual.

The present invention belongs to the fields of bioengineering and biological treatment. Disclosed are an anti-ADM monoclonal antibody or a fragment thereof and a pharmaceutical composition, a detection reagent, or a kit comprising the monoclonal antibody or the fragment thereof. Further disclosed is use of the monoclonal antibody or the fragment thereof in the preparation of a drug.

The invention relates to a multi-antigen monkey pox RNA vaccine and a preparation method thereof, and relates to the technical field of nucleic acid vaccines. The multi-antigen mRNA comprises a sequence encoding an antigenic polypeptide of the monkey pox virus or an antigenic fragment, variant or derivative thereof, the antigenic polypeptide or the antigenic fragment thereof comprising at least viral proteins of an intracellular mature virus and an extracellular envelope virus of the monkey pox virus. The invention provides a multi-antigen mRNA vaccine aiming at monkey pox viruses and a sequence, mRNA can express antigen protein in in-vitro cells, high-titer anti-monkey pox virus A29L, A33L, B6R, M1R and E8L protein IgG can be detected after a mouse is immunized, a high-titer anti-vaccinia Tian Tan strain live virus neutralizing antibody is generated, good immunogenicity is achieved, and the vaccine can be used for preparing the multi-antigen mRNA vaccine aiming at the monkey pox viruses. The important significance is realized on the prevention of the monkey pox virus.

The application provides a galactoside agglutinin 10 (Gal10) crystal and a preparation method and prepared antibody IgY and a pharmaceutical preparation thereof, and belongs to the technical field of medicines. The application uses the galactoside agglutinin 10 crystal as an antigen to prepare an egg yolk neutralizing antibody IgY capable of dissolving the Gal10 crystal, has the effects of improving rhinitis or asthma of a patient, preventing and treating rhinitis and asthma, and is safe, has no side effects, has a long-lasting curative effect, and has no drug resistance, thereby providing a safe, simple, hygienic, effective, economic and personalized treatment mode for prevention and treatment of rhinitis and asthma, and having a high market value.

The application provides a kit for detecting neutralizing antibodies of a novel coronavirus, comprising an immunochromatography test paper, the immunochromatography test paper comprising a backing plate and a sample pad, a conjugate pad, a detection pad and a water absorption pad arranged on the backing plate in sequence; the detection pad is provided with a detection line and a quality control line; the sample pad is coated with a recombinant antigen, the recombinant antigen being a fusion protein SARS-CoV-2S-RBD-Fc formed by fusing SARS-CoV-2S-RBD with the Fc fragment of IgG antibody; the conjugate pad is coated with SARS-CoV-2ACE2 labeled with nanoparticles; and the detection line is coated with a polyantibody of anti-IgG antibody. The kit for detecting the application utilizes the principle of competition and sandwich detection, can quickly and simply realize effective detection of neutralizing antibodies of the novel coronavirus, has low cost, high sensitivity and high specificity, and has a good popularization and application prospect.

The high pathogenicity of the rift valley fever virus limits the research on the pathogenic mechanism and prevention, control and treatment products of the rift valley fever virus, the offspring replication-deficient virus particles are successfully saved through a reverse genetic manipulation technology, and the virus particles do not have the capacity of multiple rounds of infection on common cells; stable replication and passage can only be realized in a cell line for providing exogenous envelope glycoprotein; in addition, the virus particle carries an exogenous indication protein and can indicate cell infection. The Rift Valley fever virus-like particle provided by the invention can be used as a Rift Valley fever biosafety secondary laboratory research platform, the establishment of the virus particle greatly simplifies tedious procedures in the Rift Valley fever virus research process, and paves a way for screening of Rift Valley fever virus neutralizing antibodies, research and development of candidate vaccines and research of pathogenic mechanisms of the Rift Valley fever viruses.

The invention relates to a ZIKV nano vaccine as well as a construction method and application thereof, the ZIKV nano vaccine is prepared by mixing an SC-Mi3 fusion protein and an EDIII-ST fusion protein, and carrying out self-assembly connection through a SpyTag connecting peptide in the SC-Mi3 fusion protein and a SpyCatcher connecting peptide in the EDIII-ST fusion protein, so as to obtain a nano particle vaccine with Mi3 as a core and ZIKV EDIII protein displayed on the surface. The SC-Mi3 fusion protein is formed by fusing a SpyCatcher connecting peptide into Mi3 nano particles, and the EDIII-ST fusion protein is formed by fusing a SpyTag connecting peptide into a ZIKV EDIII protein. The ZIKV nano vaccine can induce a strong specific neutralizing antibody aiming at ZIKV, can resist lethal attack of ZIKV and avoids ADE reaction.

The invention provides a method for purifying foot-and-mouth disease based on a method for detecting suspected positive foot-and-mouth disease virus nucleic acid, and aims to thoroughly remove foot-and-mouth disease pathogens in a group and in the environment. According to the provided method, an ELISA kit is used for detection, the kit comprises a monoclonal antibody, the amino acid sequence of a heavy chain of the monoclonal antibody is SEQ ID NO: 7, and the amino acid sequence of a light chain of the monoclonal antibody is SEQ ID NO: 9. The method comprises the following steps: enhancing immunization of pigs with unqualified antibodies, detecting foot-and-mouth disease neutralizing antibodies and VP1 antibodies after immunization, and eliminating immune antibody negative and VP1 antibody positive pigs. The ELISA kit provided by the invention is strong in stability and good in sensitivity, and when the kit is used for checking in a large-scale pig farm, the purification of the foot-and-mouth disease can be effectively realized. The purification method provided by the invention is high in accuracy and easy to popularize and apply.

The present invention provides methods of treating ischemic and traumatic central nervous system injury by administering an antagonist of the interaction between CD47 and SIRPa. Also provided are method of increasing efferocytosis after a traumatic or ischemic CNS injury by administering an antagonist of the interaction between CD47 and SIRPa.